• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2019年冠状病毒病时代免疫性血小板减少症发病率的变化：韩国一项全国性观察研究

Changes in the Incidence of Immune Thrombocytopenia in the Coronavirus Disease 2019 Era: A Nationwide Observational Study in Korea.

作者信息

Choi Young Bae, Jung Hyun Joo, Kim Hae-Rim, Jeong Soo In

机构信息

Department of Pediatrics, Ajou University School of Medicine, Ajou University Hospital, Suwon, Korea.

College of Natural Science, School of Statistics, University of Seoul, Seoul, Korea.

出版信息

Risk Manag Healthc Policy. 2023 Apr 10;16:667-676. doi: 10.2147/RMHP.S403196. eCollection 2023.

DOI:10.2147/RMHP.S403196
PMID:37064796
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10103706/
Abstract

PURPOSE

We investigated whether nonpharmaceutical interventions (NPI) to reduce the spread of coronavirus disease 2019 (COVID-19) was associated with a change in the incidence of immune thrombocytopenia (ITP).

PATIENTS AND METHODS

Using the Korean Health Insurance Review and Assessment Services (HIRA) database, individuals newly diagnosed with ITP between January 2015 and December 2020 were identified. The NPI period was defined as February 2020 to December 2020. The ITP incidence in the NPI period was compared with the mean annual incidence during the same months in the pre-NPI period and the incidence predicted by the autoregressive integrated moving average model.

RESULTS

In total, 25,723 patients were identified, and the overall annual incidence of ITP was 8.28 per 100,000 persons ([95% confidence interval (CI): 8.18-8.39]. The ITP incidence in the NPI period was 6.60 per 100,000 person-years (95% CI: 6.37-6.85), 0.77 times (95% CI: 0.74-0.80) lower than that during the pre-NPI period [8.62/100,000 (95% CI: 8.50-8.74)]. With the exception for patients aged ≥70 years, the ITP incidence was significantly lower in the NPI period than in the pre-NPI period. The most significant decline in the ITP incidence during the NPI period was observed in the 0-9 years age group [25.76/100,000 vs 14.01/100,000, <0.001; incidence rate ratio (IRR): 0.54 (95% CI: 0.51-0.58)]. The intravenous immunoglobulin-treated ITP incidence in the NPI period was 1.69/100,000 (95% CI: 1.58-1.81), 0.79 times (95% CI: 0.73-0.85) lower than that in the pre-NPI period 2.15/100,000 (95% CI: 2.09-2.21)]. The incidence of steroid-treated ITP was lower in the NPI period than in the pre-NPI period (2.73/100,000 vs 2.2/100,000, <0.001), with an IRR of 0.80 (95% CI: 0.76-0.83).

CONCLUSION

This nationwide study revealed a significant decrease in ITP incidence, particularly among children, after the implementation of NPI.

摘要

目的

我们调查了用于减少2019冠状病毒病（COVID-19）传播的非药物干预措施（NPI）是否与免疫性血小板减少症（ITP）发病率的变化相关。

患者与方法

利用韩国健康保险审查与评估服务（HIRA）数据库，确定了2015年1月至2020年12月期间新诊断为ITP的个体。NPI时期定义为2020年2月至2020年12月。将NPI时期的ITP发病率与NPI前时期相同月份的年均发病率以及自回归积分滑动平均模型预测的发病率进行比较。

结果

共确定了25723例患者，则ITP的总体年发病率为每10万人8.28例（[95%置信区间（CI）：8.18 - 8.39]）。NPI时期的ITP发病率为每10万人年6.60例（95% CI：6.37 - 6.85），比NPI前时期[8.62/10万（95% CI：8.50 - 8.74）]低0.77倍（95% CI：0.74 - 0.80）。除70岁及以上患者外，NPI时期的ITP发病率显著低于NPI前时期。NPI时期ITP发病率下降最显著的是0 - 9岁年龄组[25.76/10万对14.01/10万，<0.001；发病率比（IRR）：0.54（95% CI：0.51 - 0.58）]。NPI时期静脉注射免疫球蛋白治疗的ITP发病率为1.69/10万（95% CI：1.58 - 1.81），比NPI前时期的2.15/10万（95% CI：2.09 - 2.21）低0.79倍（95% CI：0.73 - 0.85）。NPI时期接受类固醇治疗的ITP发病率低于NPI前时期（2.73/10万对2.2/10万，<0.001），IRR为0.80（95% CI：0.76 - 0.83）。

结论

这项全国性研究显示，实施NPI后ITP发病率显著下降，尤其是在儿童中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc99/10103706/9103d786a8f9/RMHP-16-667-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc99/10103706/3ee6682fe67c/RMHP-16-667-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc99/10103706/794c6fe32121/RMHP-16-667-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc99/10103706/24f47e51a637/RMHP-16-667-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc99/10103706/1275bf41db5c/RMHP-16-667-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc99/10103706/f83aea6e771d/RMHP-16-667-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc99/10103706/9103d786a8f9/RMHP-16-667-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc99/10103706/3ee6682fe67c/RMHP-16-667-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc99/10103706/794c6fe32121/RMHP-16-667-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc99/10103706/24f47e51a637/RMHP-16-667-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc99/10103706/1275bf41db5c/RMHP-16-667-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc99/10103706/f83aea6e771d/RMHP-16-667-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc99/10103706/9103d786a8f9/RMHP-16-667-g0006.jpg

相似文献

1
Changes in the Incidence of Immune Thrombocytopenia in the Coronavirus Disease 2019 Era: A Nationwide Observational Study in Korea.2019年冠状病毒病时代免疫性血小板减少症发病率的变化：韩国一项全国性观察研究
Risk Manag Healthc Policy. 2023 Apr 10;16:667-676. doi: 10.2147/RMHP.S403196. eCollection 2023.
2
Changes in the Incidence of Optic Neuritis before and after the Coronavirus Disease 2019 Outbreak: A Nationwide Study 2017-2022.2019年冠状病毒病疫情前后视神经炎发病率的变化：一项2017 - 2022年的全国性研究
Ophthalmology. 2025 Mar;132(3):280-289. doi: 10.1016/j.ophtha.2024.09.009. Epub 2024 Sep 13.
3
The impact of non-pharmaceutical interventions on premature births during the COVID-19 pandemic: a nationwide observational study in Korea.新型冠状病毒肺炎大流行期间非药物干预措施对早产的影响：韩国一项全国性观察性研究
Front Pediatr. 2023 Jun 27;11:1140556. doi: 10.3389/fped.2023.1140556. eCollection 2023.
4
Incidence and prevalence of immune thrombocytopenia under the copayment waiver policy for pediatric patients in Korea: Data from the National Health Claims Database.韩国免共付额政策下儿科患者免疫性血小板减少症的发病率和患病率：来自国家健康索赔数据库的数据。
Lupus. 2021 Apr;30(4):655-660. doi: 10.1177/0961203321995247. Epub 2021 Feb 16.
5
Epidemiology and management of primary immune thrombocytopenia: A nationwide population-based study in Korea.原发性免疫性血小板减少症的流行病学和管理：韩国全国范围内基于人群的研究。
Thromb Res. 2017 Jul;155:86-91. doi: 10.1016/j.thromres.2017.05.010. Epub 2017 May 11.
6
Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis.美国临床实践中的原发性免疫性血小板减少症：诊断后 12 个月内的发病率和医疗保健负担。
J Med Econ. 2020 Feb;23(2):184-192. doi: 10.1080/13696998.2019.1669329. Epub 2019 Oct 9.
7
Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection.120908名美国丙型肝炎病毒感染退伍军人中免疫性血小板减少性紫癜和自身免疫性溶血性贫血的风险
Arch Intern Med. 2009 Feb 23;169(4):357-63. doi: 10.1001/archinternmed.2008.576.
8
Incidence and disease burden of autoimmune inflammatory rheumatic diseases after non-pharmaceutical interventions in the COVID-19 era: A nationwide observational study in Korea.在 COVID-19 时代非药物干预后自身免疫性炎症性风湿病的发病率和疾病负担：韩国全国性观察研究。
Int J Rheum Dis. 2024 Apr;27(4):e15144. doi: 10.1111/1756-185X.15144.
9
Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database.《全科医学研究数据库中儿童免疫性血小板减少症的流行病学》。
Br J Haematol. 2010 Jun;149(6):855-64. doi: 10.1111/j.1365-2141.2010.08176.x. Epub 2010 Apr 4.
10
Impact of Nonpharmaceutical Interventions on the Incidence of Respiratory Infections During the Coronavirus Disease 2019 (COVID-19) Outbreak in Korea: A Nationwide Surveillance Study.非药物干预对韩国 2019 年冠状病毒病（COVID-19）爆发期间呼吸道感染发病率的影响：一项全国性监测研究。
Clin Infect Dis. 2021 Apr 8;72(7):e184-e191. doi: 10.1093/cid/ciaa1682.

本文引用的文献

1
Influence of COVID-19-Related Interventions on the Number of Inpatients with Acute Viral Respiratory Infections: Using Interrupted Time Series Analysis.新冠疫情相关干预措施对急性病毒性呼吸道感染住院人数的影响：使用中断时间序列分析。
Int J Environ Res Public Health. 2023 Feb 4;20(4):2808. doi: 10.3390/ijerph20042808.
2
Changes in Respiratory Pathogens before and after the COVID-19 Pandemic (2018-2021).新冠疫情前后（2018-2021 年）呼吸道病原体的变化。
Biomed Res Int. 2022 Oct 10;2022:1324052. doi: 10.1155/2022/1324052. eCollection 2022.
3
Impact of restrictive measures due to the Covid-19 pandemic on the incidence of immune thrombocytopenia in children: an Italian single center experience.
Covid-19 大流行期间限制措施对儿童免疫性血小板减少症发病率的影响：意大利单中心经验。
Pediatr Hematol Oncol. 2023 Mar;40(2):192-195. doi: 10.1080/08880018.2022.2095473. Epub 2022 Jul 4.
4
Effect of a Regional Outbreak of Coronavirus Disease 2019 on Kawasaki Disease in Korea.2019年冠状病毒病地区性疫情对韩国川崎病的影响。
Risk Manag Healthc Policy. 2022 Apr 19;15:739-745. doi: 10.2147/RMHP.S359781. eCollection 2022.
5
Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic.在 COVID-19 大流行期间，疫苗安全研究中关注结局的发生率变化。
Vaccine. 2022 May 20;40(23):3150-3158. doi: 10.1016/j.vaccine.2022.04.037. Epub 2022 Apr 18.
6
Quantifying the Impact of COVID-19 Nonpharmaceutical Interventions on Influenza Transmission in the United States.量化 COVID-19 非药物干预措施对美国流感传播的影响。
J Infect Dis. 2021 Nov 16;224(9):1500-1508. doi: 10.1093/infdis/jiab485.
7
Reduction in Kawasaki Disease After Nonpharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea.新冠疫情时代非药物干预后川崎病发病率的下降：韩国一项全国性观察性研究
Circulation. 2021 Jun 22;143(25):2508-2510. doi: 10.1161/CIRCULATIONAHA.121.054785. Epub 2021 Jun 7.
8
Impact of Social Distancing on Kawasaki Disease-associated Hospitalization, South Korea.社会隔离对韩国川崎病相关住院治疗的影响
Pediatr Infect Dis J. 2021 Oct 1;40(10):e383-e384. doi: 10.1097/INF.0000000000003202.
9
Epidemiology and Viral Etiology of Pediatric Immune Thrombocytopenia through Korean Public Health Data Analysis.通过韩国公共卫生数据分析探讨儿童免疫性血小板减少症的流行病学及病毒病因
J Clin Med. 2021 Mar 25;10(7):1356. doi: 10.3390/jcm10071356.
10
Incidence and prevalence of immune thrombocytopenia under the copayment waiver policy for pediatric patients in Korea: Data from the National Health Claims Database.韩国免共付额政策下儿科患者免疫性血小板减少症的发病率和患病率：来自国家健康索赔数据库的数据。
Lupus. 2021 Apr;30(4):655-660. doi: 10.1177/0961203321995247. Epub 2021 Feb 16.